leadf
logo-loader
AIM:AMYT NASDAQ:AMYT

Amryt Pharma PLC

 Receive alerts
Market:
AIM
Market Cap:
£332.85 m
Price
210.00 GBX
Change
0.96%
52 weeks high
250.00
52 weeks low
80.00
07.21

Director Interviews

In brief

Amryt Pharma is a commercial stage pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of people with rare and orphan diseases.

In brief Deep dive Research Latest news Insight Interviews

Deep dive We explore the investor case for growth companies

Amryt Pharma makes good progress after US deal
Amryt Pharma PLC -

Snapshot

  • A revenue-generating orphan drugs company
  • Completed a transformational deal
  • Expected to be a high growth business  
Open Deep dive

Latest news

Amryt Pharma set to receive orphan designation for pre-clinical skin treatment

5 days, 17 hours ago

Amryt Pharma hails phase III success for skin gel as "significant milestone"

1 week, 5 days ago

Amryt Pharma ups revenue estimate as sales momentum builds

on 6/8/20

Amryt Pharma: Cantor Fitzgerald backs orphan drug group for NASDAQ success

on 9/7/20

Proactive news headlines: Iconic Labs, Panther Metals, MaxCyte, Oncimmune …

on 8/7/20

Amryt appoints Swixx as Central Europe distributor for fast-growing leptin...

on 3/6/20

Amryt Pharma "significantly EBITDA positive" ahead of schedule

on 11/5/20

Amryt Pharma unveils brand name for phase III cream for rare genetic skin...

on 7/5/20

Watch

Ocado Group PLC - Big caps Market report: FTSE gains despite uncertain UK labour market outlook
5 days, 11 hours ago
AstraZeneca - Market report: Sterling six week lows despite further lockdown woes Big caps Market report: Sterling six week lows and further lockdown woes
1 week, 5 days ago
Amryt Pharma PLC - Amryt Pharma announces 'positive' results from rare skin disease trial Small caps Amryt Pharma announces 'positive' results from rare skin disease trial
1 week, 5 days ago
Amryt Pharma releases Q-2 financials that show strong revenue growth as company issues guidance Director Interviews Amryt Pharma releases Q-2 financials that show strong revenue growth as company issues guidance
on 6/8/20
View all